Monte Rosa Therapeutics (GLUE) Research & Development (2023 - 2025)
Historic Research & Development for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $36.7 million.
- Monte Rosa Therapeutics' Research & Development rose 3281.43% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.4 million, marking a year-over-year increase of 2599.88%. This contributed to the annual value of $121.6 million for FY2024, which is 924.85% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Research & Development of $36.7 million as of Q3 2025, which was up 3281.43% from $30.7 million recorded in Q2 2025.
- Monte Rosa Therapeutics' 5-year Research & Development high stood at $38.9 million for Q4 2024, and its period low was $26.8 million during Q1 2023.
- Its 3-year average for Research & Development is $30.2 million, with a median of $28.3 million in 2023.
- Over the last 5 years, Monte Rosa Therapeutics' Research & Development had its largest YoY gain of 4323.2% in 2024, and its largest YoY loss of 351.15% in 2024.
- Over the past 3 years, Monte Rosa Therapeutics' Research & Development (Quarter) stood at $27.1 million in 2023, then skyrocketed by 43.23% to $38.9 million in 2024, then fell by 5.63% to $36.7 million in 2025.
- Its Research & Development was $36.7 million in Q3 2025, compared to $30.7 million in Q2 2025 and $32.2 million in Q1 2025.